Results 131 to 140 of about 29,286 (231)

Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report

SAGE Open Medical Case Reports
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase ...
Ryan Sabour, Sohrab Kharabaf, Eric Frazier, Matthew Nguyen, Dao Le, Jonathan Zuckerman, Ramy Hanna   +6 more
doaj   +1 more source

Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
Mohammad Shahzaib Qadir, Shereen Farooq, Omer Jamy   +2 more
wiley   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Harnessing Trace Elements: Novel Radiosensitization Strategies for Enhanced Cancer Radiotherapy

Rare Metals, Volume 45, Issue 6, June 2026.
ABSTRACT Radiotherapy (RT) is one of the core methods of comprehensive cancer treatment. Globally, more than 40% of cancer patients rely on radiotherapy to achieve tumor control, cure or palliative relief. However, radiation resistance, immunosuppression and normal tissue injury limit its clinical application.
Yuhuan Zhang, Yizhi Ge, Hongguang Xiang, Ji Liu, Yu Tian, Yan Shen, Dan Zong   +6 more
wiley   +1 more source

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

Терапевтический архив, 2009
Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib. Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.
Ol'ga Yur'evna Vinogradova, Anna Grigor'evna Turkina, Aleksandra Valer'evna Vorontsova, Ekaterina Yur'evna Chelysheva, Galina Anatol'evna Gusarova, S V Kuznetsov, Svetlana Rudol'fovna Goryacheva, Manana Aleksandrovna Sokolova, Evgeniy Mikhaylovich Abakumov, Ol'ga Veniaminovna Stakhina, Elena Vasil'evna Domracheva, Andrey Vital'evich Misyurin, Nina Dmitrievna Khoroshko, O Yu Vinogradova, A G Turkina, A V Vorontsova, E Yu Chelysheva, G A Gusarova, S V Kuznetsov, S R Goryacheva, M A Sokolova, E M Abakumov, O V Stakhina, E V Domracheva, A V Misyurin, N D Khoroshko   +25 more
doaj  

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, Volume 31, Issue 6, Page 561-577, June 2026.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Non‐ICANS neurotoxicity after BCMA‐directed CAR‐T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co‐management

HemaSphere, Volume 10, Issue 6, June 2026.
Jan‐Michael Werner, Philipp Gödel, Norbert Galldiks, Christopher Krone, Michael Schroeter, Udo Holtick, Ruth Flümann, Gilbert Wunderlich, Michael Hallek, Gereon R. Fink, Christoph Scheid, Oezguer A. Onur, Tim Richardson   +12 more
wiley   +1 more source

The Aging Microenvironment Shapes Angiogenic Remodeling in IBD‐Associated Colorectal Carcinogenesis

Aging Cell, Volume 25, Issue 6, June 2026.
In IBD, chronic inflammation promotes cellular senescence across epithelial, stromal, endothelial, and immune compartments. The resulting SASP drives pathological angiogenesis, vascular dysfunction, hypoxia, and immune suppression, thereby facilitating progression from inflammation to dysplasia and colitis‐associated colorectal cancer.
Ruoshu Duan, Qingyu Chen, Yuan Xu, Ye Yan, Sujing Jiang   +4 more
wiley   +1 more source

Treatment of restenosis and stenosis with dasatinib

, 2014
A method for treating or inhibiting artery obstructive disease, such as restenosis after angioplasty and stenting procedures and stenosis after coronary artery bypass surgery, in a subject by administering to the subject a therapeutically effective ...
Wu, Jie, Bhalla, Kapil N., Chen, Zhengming   +2 more
core